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Abstract
Objective: Perceived cognitive dysfunction in fibromyalgia (FM), “fibrofog,” is common. Prior 
laboratory-based studies have limited our understanding of cognitive function in FM in daily life. The 
aim of this study is to explore levels of subjective and objective cognitive functioning and the 
association between subjective and objective aspects of cognition in persons with and without FM in 
the lived environment. 
Methods: Participants (n=50 adults with FM; n= 50 adults without FM matched on age, sex, and 
education) completed baseline measures of subjective and objective (NIH Toolbox) cognitive 
functioning. Then, they completed ecological momentary assessments of cognitive clarity and speed 
and tests of processing speed and working memory, via a smart phone app, 5X/day for 8 days. 
Results: On baseline objective measures, the FM group demonstrated poorer cognitive functioning 
across three NIH Toolbox tests. There were no strong correlations between subjective and objective 
cognitive functioning in both the FM and control group. In the lived environment, the FM group 
demonstrated poorer subjective cognition and objective working memory; groups did not differ on 
processing speed. Momentary ratings of subjective cognitive dysfunction were significantly related to 
changes in objective processing speed but not working memory, with no group differences. 
Conclusion: Findings indicate worse lab-based and ambulatory subjective and objective cognitive 
function for those with FM compared to those without FM. Similar associations between measures of 
subjective and objective cognitive functioning for the groups suggest that people with FM are not 
overstating cognitive difficulties. Future research examining contributors to ambulatory fibrofog is 
warranted. 
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Significance and Innovations
 This study investigates within-day fluctuations in subjective and objective cognitive function in 
the lives of people with fibromyalgia (FM) compared to a non-FM group.
 At baseline, the FM group showed moderate performance deficits and reported moderately 
worse cognitive function than the non-FM group; the groups were similar with regard to the 
correlation between subjective and objective measures of cognitive function.
 On ambulatory assessment, the FM group had poorer subjective cognitive function and 
objective working memory, but not worse processing speed compared to the non-FM group.
 For both groups, momentary changes in processing speed, but not working memory, were 
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Introduction
Approximately 5 million adults in the United States are diagnosed with fibromyalgia (FM), a 
musculoskeletal disorder where pain is usually accompanied by a constellation of physical and 
mental symptoms (1-4). Approximately 70% of individuals with FM endorse cognitive dsyfunction, 
known as “fibrofog” (3-5), which contributes to negative health perceptions and difficulty maintaining 
relationships, working, communicating, driving, organizing, and initiating activities of daily life (3-5). 
Despite growing evidence that FM is also associated with objective dysfunction across multiple 
cognitive domains (6, 7), the totality of the evidence for impaired cognitive functioning in FM is 
equivocal, with a number of studies showing no difference or limited/focal differences in cognitive 
impairment between people with and without FM (8-17).  
One gap is in our knowledge of fibrofog and objective cognitive functioning where it matters 
most – in the everyday lives of people with FM. Research to date has relied on cross-sectional 
designs and standardized neuropsychological tests, in a clinical environment, at a single visit. The 
controlled, artificial nature of this testing environment is fundamentally different from the real-world 
environment in which people perform cognitively demanding tasks (18, 19); consequently, these 
studies lack ecological validity and their relationship to performance in the real world remains an 
open question (19, 20). The “snapshot” of cognitive function from cross-sectional neuropsychological 
studies is further limited because it fails to capture intra-individual variations in cognitive function (21, 
22). Variability in cognitive function in FM is important because fluctuating cognitive performance 
may itself be an indicator of poor cognition (23, 24) and of vulnerability to future cognitive declines 
(25, 26).  Examining the variability of cognition within a person may also provide new insights into the 
association between subjective (perceived) and objective (performance-based) cognitive dysfunction 
in FM. 
A number of studies have demonstrated a discrepancy between subjective and objective 
cognitive functioning in FM (16, 27, 28), with depressed mood, alertness/hypersensitivity to fibrofog, 
and fatigue implicated as contributing factors to the disconnect. We lack insight about whether these 
findings of poor correlation between subjective and objective cognition at a between-person level are 
different between those with and without FM and whether this is also seen in daily life as difficulty 
accurately perceiving small moment-to-moment fluctuations in objective cognitive functioning in FM. 
The goal of this study is to use ambulatory assessment methods to examine subjective and 
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compared the groups in terms of levels of cognitive functioning (subjective, and objective processing 
speed and working memory) and association between subjective and objective cognitive functioning. 
We expected the FM group to show lower levels of subjective and objective cognitive functioning on 
both baseline and ambulatory measures. But, we expected no group differences in terms of the 




Volunteers were eligible if they were: 1) ≥18 years of age; and 2) able to fluently converse 
and read (6th grade level) in English. Volunteers were excluded if they endorsed: 1) comorbid 
neurological disorder, learning disorder, or cognitive impairment; 2) current alcohol or recreational 
drug dependence or prolonged (≥5 years) history of substance dependence; 3) visual or hearing 
impairment that would preclude cognitive testing; 4) diagnosis of untreated obstructive sleep apnea; 
or 5) atypical sleep/wake pattern (e.g. night-shift workers). Participants with FM fulfilled the 2016 
American College of Rheumatology survey criteria (29); participants in the control group did not meet 
the criteria for FM and were matched to already-enrolled participants with FM based on sex, age, 
and education. 
Study Procedures
Prior to initiation of study activities, the Medical Institutional Review Board at the University of 
Michigan (UM) approved all study procedures. Participants were recruited from the UM, through 
existing patient registries, community groups, placement of fliers in health centers and community 
settings, and advertisement on a university-based recruitment website (www.UMHealthresearch.org). 
Volunteers were screened for eligibility over the phone and provided written informed consent prior to 
beginning study activities. Data were collected between January and August, 2018. 
Participation in this study involved a ~90-minute baseline visit followed by an 8-day home 
monitoring period (i.e. a 1-day “run-in” period, followed by 7 days of data collection). At the baseline 
visit, enrolled participants completed a battery of self-report measures and standardized cognitive 
testing and were given data collection devices. At the conclusion of the home monitoring period, 
participants returned the devices via a postage paid return box to the lab for data processing. 
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Participants were issued a ZTE Axon 7 mini smartphone, with a 5.2” display (1080 x 1920 
pixels) and programmed with a customized study-specific app to administer ecological momentary 
assessment (EMA) measures and ambulatory cognitive tests. Participants were instructed to initiate 
the first of the five daily EMA and cognitive testing sessions upon waking. For the following four 
sessions, the smartphone was programmed to play an audible alert to prompt the respondent to 
complete EMA and cognitive assessments; alerts were programmed on a quasi-random schedule 
based on each person’s typical waking time with scheduled intervals between prompts ranging 
between 3-4.5 hours(18). 
Measures
Baseline self-report measures
Participants completed surveys of demographics, medications, and validated symptom 
surveys. The Multidimensional Inventory of Subjective Cognitive Impairment (MISCI)(30) consists of 
10-items that assess cognitive functioning, rated on two scales ranging from 1=not at all/never to 
5=very much/very often, summed and converted to a T-score metric (Mean=50, SD=10); higher 
scores indicate better functioning. Pain was assessed with the Patient Reported Outcome 
Measurement Information System (PROMIS) Pain Intensity 3a short form, which assesses worst and 
average pain in the past 7 days (1=“no pain” to 5=“very severe” scale) and current level of pain 
(1=“no pain” to 5=“very severe”). Scores were summed and converted to T-score metric (Mean=50, 
SD=10); higher scores indicate more pain. Depressive symptoms were measured with the Patient 
Health Questionnaire–8 (PHQ-8)(31) that assesses the frequency of 8 depressive symptoms in the 
past 2 weeks. Scores range from 0-24; higher scores indicate greater depressive symptomatology. 
Fatigue was assessed with a 4-item short form from the PROMIS fatigue item bank (32); scores are 
on a T-score metric with a Mean=50 and SD=10. Higher scores are indicative of higher fatigue.
Baseline cognitive tests
Four National Institutes of Health (NIH) Toolbox (33) cognitive tests were administered via the 
NIH Toolbox iPad App (34). The Flanker task is a measure of attention and inhibitory control that 
requires participants to focus on a given stimulus while inhibiting attention stimuli flanking the target. 
The List Sorting task is a test of working memory where participants recall and sequence stimuli 
presented both orally and visually. The Dimensional Change Card Sort is a test of cognitive flexibility 
and attention where pictures are presented varying by shape and color; the target dimension to be 
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is a measure of processing speed where participants are given 85 seconds to respond to as many 
stimuli as possible, discerning whether two simple pictures are identical or not. The NIH Toolbox 
provides a fully corrected T-score for each test (Mean=50, SD=10) corrected for age, education, 
gender, and race/ethnicity. Higher scores indicate better functioning. 
Ambulatory Assessments
A study-specific smart phone app was programmed to administer EMA measures and 
cognitive tests in a single assessment/testing session. 
Ecological momentary assessment
Subjective cognitive functioning was assessed with two items from the PROMIS Applied 
General Concerns (35) item bank, adapted for momentary assessment. The items “How slow is your 
thinking right now?”, rated on a scale of 0–100, where 0=my thinking is very fast to 100=my thinking 
is very slow, and “How foggy is your thinking right now?” rated on a scale of 0-100 where 0=my 
thinking is very clear to 100=my thinking is very foggy, were averaged to produce an aggregate score 
where higher scores indicate worse subjective cognitive functioning. Cronbach’s alpha=0.95, 
indicating excellent internal consistency. 
Ambulatory objective cognitive tests 
Two brief, valid, and reliable cognitive tests (18), were administered via the study-specific 
smart phone app following administration of EMAs.
Symbol Search Test
The Symbol Search is a test of processing speed, where participants saw a row of four 
symbol pairs at the top of the screen and two symbol pairs at the bottom of the screen. Participants 
decided, as quickly as possible, which symbol pair at the bottom matches a symbol pair at the top 
and select the matching pair by touching their selection. Seventy-five percent of trials contained a 
lure stimulus, meaning that one of the two symbols on a not-matching pair matched one of the 
symbols at the top (but the pair did not match).  Stimuli were presented until a response was 
provided. Accuracy and reaction time (milliseconds) were recorded. Sixteen trials were administered 
per testing session. Two variables were calculated for sessions where accuracy was ≥70%: average 
reaction time and standard deviation (variability) in reaction time per session.
Symbol Search session accuracy was used to assess participant effort in completing the test. 









This article is protected by copyright. All rights reserved
with accuracy rates of about 50%. Intentional poor performance (“faking bad”) would likewise be 
expected to correspond with low accuracy and could be expected to play a role in cases where 
accuracy was <50%.  Accuracy of <70% was used as a conservative cut-point to indicate poor effort; 
this is consistent with the procedures used in the study to validate these measures (18).
Dot Memory Test
The Dot Memory is a test of working memory. Each trial consists of 3 phases: encoding, 
distraction, and retrieval. During the encoding phase, the participant is asked to remember the 
location of three red dots appearing on a 5X5 square grid. After 3-seconds, the grid is removed and 
the distraction phase begins, during which the participant is required to touch the F’s in an array of 
E’s. After the distraction task, an empty 5X5 square grid is presented and the participant must place 
the red dots (by touching the empty squares) in the correct locations. Participants press “Done” when 
finished. Four test trials are administered each session. Euclidian distance, or the collective distance 
of the three dots from their correct locations (total error), was calculated. Three variables were 
calculated for Dot Memory: Average, maximum, and standard deviation of Euclidian distances across 
the four trials of each session. 
Data analysis
Descriptive statistics for demographic and baseline measures were calculated. Independent 
samples t-tests were used to test group differences in baseline survey and cognitive test scores. 
Group differences in correlations between subjective and objective cognitive functioning were also 
tested (36). Graphs of subjective and objective cognitive functioning were plotted using mean scores 
at each within-day measurement time point collapsed across days and by group. Linear regression 
was used to determine whether group membership (FM/non-FM) predicted aggregate subjective or 
objective cognitive functioning scores across all days of study. Six objective functioning scores were 
investigated in separate analyses: three for processing speed (mean, median, and standard 
deviation of response times; Symbol Search test), and three for working memory (mean, maximum, 
and standard deviation of the error scores; Dot Memory test). The first day of at-home data collection 
was excluded as a “training day”. To account for practice-related improvements in performance on 
ambulatory cognitive tests, models were adjusted for session number (a continuous variable that 
reflected the number of times the participant had completed the cognitive tasks). To investigate 
associations between momentary changes in subjective and objective cognitive functioning, person-
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participant’s mean for the variable of interest) were included in separate multilevel models, with 
subjective cognitive functioning as the outcome, adjusted for session number (i.e., possible practice 
effects); in a final model, an interaction term between the objective cognitive functioning variable and 
group was used to test for group differences. Analyses were performed using Stata (Version 15, 
StataCorp, College Station, TX). For significance tests, a p value of less than 0.05 was used as the 
threshold to determine statistical significance. 
Results
One hundred participants (50 FM, 50 non-FM) enrolled and provided data. The sample was 
mostly female and white, with an average age of 45 years; the FM group had a significantly higher 
rate of unemployed (χ2 (1, N=100) =5.88, p=0.02; Table 1). Participants were generally compliant 
with the data collection protocol, providing data for an average of 90.9% of possible assessment 
sessions; the FM group had, on average, 91.2% complete data and the Non-FM group 90.5%.
Group comparisons of baseline measures
The FM group reported significantly worse scores on subjective cognition, and measures of 
depressed mood, pain, and fatigue, and demonstrated poorer objective cognitive function on NIH 
Toolbox tests; however, differences on cognitive tests were <1SD (Tables 1 and 2). The FM group 
reported higher levels of taking medications that could affect cognitive functioning; chi-square tests 
indicate significant group differences across all six medication categories listed (all p<0.05; Table 1).
Correlations between baseline subjective and objective cognitive function
The groups did not differ in terms of the correlations between subjective (MISCI scores) and 
objective cognition on the NIH Toolbox tests (p>0.06 for all test of group differences). For both 
groups, higher subjective cognitive functioning was correlated with better objective cognitive 
performance on all NIH Toolbox tests, except for the List Sorting task, which showed no significant 
correlation with the MISCI in either group. 
Effort on ambulatory cognitive testing
Accuracy on the Symbol Search task suggested good effort for both groups. Accuracy was 
>70% for 3688/3781 (98.8%) of all sessions. The groups did not differ in terms of accuracy rates. For 
the FM group, accuracy was >70% for 1784/1813 (98.4%) of sessions (range=43.75-100.00%; 
Median=100.00, Mean=95.81, SD=6.83). For the non-FM Group, accuracy was >70% for 1904/1918 
(99.2%) of sessions (range=18.75-100.00%; Median=100.00; Mean=95.79; SD=6.32). Sixteen 
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accuracy. Of these, four participants (n=3 FM, n=1 non-FM), had multiple sessions with low accuracy 
(range=5–12 sessions) and were identified as possible cases of low effort. No reaction time variables 
were calculated for low-accuracy sessions. 
Sensitivity analyses, excluding the four participants who demonstrated repeated low 
accuracy/effort, were conducted for all ambulatory cognition analyses. The results with/without these 
four people did not change the magnitude or significance of any results. Therefore, results for the full 
sample are reported. 
Aggregate ambulatory cognitive functioning scores 
The FM group had poorer mean aggregate subjective cognitive functioning, and poorer 
working memory (Dot Memory test mean error score, maximum error score, and standard deviations 
of the error scores), all p<0.01. Although the FM group had, on average, slower processing speed 
(Symbol Search), the difference compared to the non-FM group was not statistically significant 
(Table 3). Standard deviation variables for reaction time (Symbol Search) and working memory (Dot 
Memory) reflect intra-individual variability in objective performance on these two cognitive tests 
(Table 3).  While the FM group exhibited higher within-person variability, in absolute terms, for both 
reaction time and working memory, this group difference was statistically significant for working 
memory only. Plots of mean subjective and select objective cognitive functioning scores at each daily 
time point, by group are depicted in Figures 1 and 2. 
Associations between within-person subjective and objective cognitive functioning
Irrespective of group membership and practice effects, significant associations were 
observed between within-person momentary changes in response time (mean, median, and standard 
deviation of response times) and subjective cognitive functioning. In contrast, there were no 
significant associations between momentary changes in working memory (mean, maximum, SD of 
error for the session) and subjective cognitive functioning (Table 4). Analyses that tested the 
interaction between objective test performance and group membership in predicting subjective 
cognitive function showed no evidence of a group effect on the association between any objective 
cognition variable and subjective cognitive function (all p>0.16). 
Discussion
This study provides initial evidence of the characteristics of subjective (“fibrofog”) and 
objective cognitive dysfunction in the daily lives of those with FM. Prior to examining cognitive 
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the laboratory, using a standardized battery of measures. The FM group reported worse cognitive 
function compared to the non-FM group, with subsample scores for FM approaching 1SD lower than 
scores for the non-FM group. Consistent with prior research demonstrating worse performance on 
standardized neurocognitive testing in FM, the FM group demonstrated worse attention (Flanker & 
Dimensional Card Sort tests), working memory (List Sorting), and processing speed (Pattern 
Comparison) compared to the non-FM group; however, the between-group differences in test 
performance were modest (<1SD). Furthermore, with the exception of scores on the Flanker task, 
which were <1SD below the normative mean, the FM group was within ½ SD of the normative 
sample mean of 50. In sum, analyses of baseline data show that on standard lab-based cognitive 
tests and surveys of cognitive function, the FM group showed moderate performance deficits and 
reported moderately worse cognitive dysfunction; The FM group reported far more subjective 
cognitive difficulties compared to those without FM, but findings that the FM group did not differ in 
terms of correlation between subjective and objective measures suggest that these complaints were 
not out of proportion to the cognitive deficits they demonstrated on baseline tests. 
In terms of real-world ambulatory cognitive functioning, those with FM demonstrated poorer 
subjective cognitive dysfunction and objective working memory, but not significantly worse 
processing speed, compared to those without FM. The lack of processing speed impairment in the 
FM group is in contrast to previous studies showing slower cognitive processing in FM (37-40). 
Partially consistent with expectations, the FM group also showed greater intra-individual variability in 
working memory, but not in processing speed, compared with controls. Given that the lab-based test 
of processing speed showed significant group differences, the finding that the real-world test of this 
domain did not reveal group differences was unexpected. Reasons for lack of group differences on 
this ambulatory test may be due to a number of factors that warrant further exploration. It may be that 
the ambulatory reaction time task used in this study is not adequately sensitive to actual group 
differences in processing speed; processing speed is a relatively basic, “lower-order” cognitive 
domain that underlies and mediates higher-order cognitive functions, such as executive functioning 
and memory (41, 42). As such, deficits in processing speed in FM may be relatively modest 
compared with FM-related deficits in higher order cognitive domains. This is consistent with findings 
from a recent meta-analysis (6) showing that a specific aspect of executive functioning – inhibitory 
control – showed the largest effect size between people with FM and healthy controls, whereas 
processing speed showed a relatively smaller effect (6). Like the results from this meta-analyses, 









This article is protected by copyright. All rights reserved
that the ambulatory Symbol Search testing sessions may not have been challenging or lengthy 
enough to be sensitive to FM-related deficits. For this and other unidentified reasons, it may be that 
group differences in processing speed only emerge in the controlled environment of the laboratory 
and not in real-world settings. 
Findings for focal deficits (worse working memory but not worse processing speed) for the 
FM subgroup, combined with comparable Symbol Search accuracy rates for the two groups, do not 
suggest that people with FM are demonstrating poor test motivation, “faking bad”, or global 
impairment. Previous studies have shown evidence of poor effort on tests among people with FM 
seeking disability benefits (43). But, even in studies that have found evidence of high rates of poor 
effort on cognitive testing in FM, effort did not totally explain dyscognition (44) and was not found at a 
higher rate in FM compared to other chronic pain conditions (16). Still, other studies have found no 
evidence for poor effort in FM (10, 45, 46) or for even greater achievement motivation in those with 
FM compared to age-matched controls (47).
Consistent with findings for baseline data, the association of subjective and objective 
cognitive functioning in daily life were not significantly different for those with compared to without 
FM. For both groups, only fluctuations in processing speed, but not working memory, were 
significantly related to concurrent ratings of subjective cognitive functioning such that times of worse 
than usual reaction time were associated with lower subjective cognitive clarity and speed. It is 
plausible that the lack of an association between working memory and subjective cognitive 
dysfunction is due to the fact that perceived memory ability was not assessed in the EMA items, 
which assessed cognitive clarity and speed. The finding that the groups were similar in terms of 
moment-to-moment correspondence between reaction time and subjective cognition does not 
support perceptual hypersensitivity to or perceptual exaggerations of fluctuations in objective 
cognitive performance in persons with FM. 
Study Limitations
Although this study represents a crucial step in improving the ecological validity of cognitive 
assessment of fibrofog by assessing performance in the lived environment, the tests did not assess 
performance of real-world cognitive tasks. We assessed a relatively limited number of cognitive 
domains; it may be that larger group differences would emerge on tests of other domains (e.g., 
executive functioning) (6). The study did not include a standardized assessment of effort on baseline 
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low rates of poor effort on ambulatory tests of cognition and removal of individuals who demonstrated 
occasional poor effort did not alter results. Although data on employment status was collected, we 
did not assess disability status, and therefore cannot comment on its impact on performance. In this 
first ambulatory study of cognitive function in FM, we aimed to examine how people with FM differ 
from individuals without FM and without significant symptoms (e.g., pain, fatigue); future studies that 
compare people with FM to people without FM but with chronic pain and fatigue would provide 
additional, crucial insights into the characteristics and mechanisms of fibrofog. Such comparisons are 
critical to understanding which aspects of fibrofog are related to having chronic pain (generally) and 
which are unique to FM. Fibromyalgia symptoms are observed on a spectrum, often referred to as 
fibromyalgianess (48-50); as such, FM/non-FM dichotomies such as the one considered here 
essentially mask both within-group diversity in overall fibromyalgianess and the overlap between 
groups in terms of distribution of specific symptoms (e.g., fatigue). The association between cognitive 
functioning and both fibromyalgianess and specific symptom burden profiles warrants examination in 
larger and more diverse samples. Our aim was to examine and compare subjective and objective 
cognitive functioning in adults with and without FM. Accordingly, we did not adjust for distinguishing 
symptoms of FM in our statistical models (e.g. pain, fatigue, depression). However, future analyses 
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Figure Legend
Figure 1. Plots of means for self-reported cognitive dysfunction by group at each within-day time 
point.  
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Figure 2. 
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Mean (SD) 45.1 (13.9) 44.9 (13.9) 45.2 (14.0)
Range 18–73 20–70 18–73
Female, N (%) 88 (88%) 44 (88%) 44 (88%)
Education 















White 81 (81%) 43 (86%) 38 (76%)
Black 13 (13%) 5 (10%) 8 (16%)
Bi/multi-racial 3 (3%) 2 (4%) 1 (2%)
Asian 3 (3%) 0 (0%) 3 (6%)
Medication Categories, N (%)
Opioid 16 (32%) 1 (2%)
SSRI 21 (42%) 9 (18%)
Tricyclic antidepressant 5 (10%) 0 (0%)
Pregabalin/gabapentin 8 (16%) 2 (4%)
Benzodiazepine 9 (18%) 2 (4%)
Sleep Aid 13 (26%) 0 (0%)
Symptoms (mean, SD)
PROMIS pain intensity T-
score
45.0 (11.4) 54.3 (6.1) 35.6 (6.8)
PROMIS fatigue experience 
T-score
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Patient Health 
Questionnaire-8 (total score)
6.2 (5.9) 10.6 (5.2) 1.8 (2.1)
Note. Percentages may total to >100 because participants could select more than one 
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Table 2. Baseline cognitive tests group comparisons





Multidimensional Inventory of 
Subjective Cognitive Impairment 
(MISCI)
(mean, SD)
45.54 (2.64) 54.04 (5.57) -11.80 <0.001
NIH-Toolbox Cognitive Tests (mean, SD)
Flanker test 39.98 (9.50) 43.78 (8.17) -2.14 0.03
List sorting task 49.34 (10.66) 53.18 (8.32) -2.01 0.05
Dimensional Change Card Sort test 46.38 (11.94) 54.76 (13.20) -3.33 <0.01
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Mean difference (95% CI)







-31.47 (-37.75 to -25.20)
p<0.001
Processing speed: Symbol search task (millisecs)




-187.59 (-459.84 to 84.66)
p=0.18




-176.97 (-433.08 to 79.13)
p=0.17






-111.14 (-243.92 to 21.64)
p=0.10
Working memory: Dot memory task (Euclidean distance)












-0.71 (-1.14 to -0.28)
p=0.001






-0.21 (-0.35 to -0.07)
p=0.003
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Table 4. The association between within-person variation in objective cognitive function and 
momentary self-reported cognitive function (criterion variable) adjusted for Group †
Effect 
estimate
SE 95% CI p
Within-person variation in processing speed: symbol search task mean response time
Intercept 48.10 2.43 43.33, 52.87 <0.001
Session number 0.03 0.04 -0.05, 0.12 0.43
Person-centered mean response time 0.006 0.001 0.004, 0.007 <0.001
Group -31.31 3.15 -37.48, -25.13 <0.001
Within-person variation in processing speed: symbol search task median response time
Intercept 48.08 2.44 43.30, 52.86 <0.001
Session number 0.04 0.04 -0.05, 0.12 0.42
Person-centered median response time 0.006 0.001 0.004, 0.008 <0.001
Group -31.31 3.15 -37.49, -25.13 <0.001
Within-person variation in processing speed: symbol search task standard deviation of 
response times
Intercept 49.13 2.41 44.41, 53.85 <0.001
Session number -0.03 0.04 -0.11, 0.05 0.51
Person-centered SD of response times 0.003 0.001 0.002, 0.005 <0.001
Group -31.32 3.15 -37.49, -25.14 <0.001
Within-person variation in working memory: dot memory task – mean error
Intercept 49.50 2.41 44.77, 54.22 <0.001
Session number -0.04 0.04 -0.12, 0.04 0.29
Person-centered mean error -0.10 0.41 -0.91, 0.71 0.80
Group -31.45 3.15 -37.63, -25.28 <0.001
Within-person variation in working memory: dot memory task – maximum error
Intercept 49.53 2.41 44.80, 54.25 <0.001
Session number -0.05 0.04 -0.12, 0.03 0.27
Person-centered maximum error -0.16 0.23 -0.61, 0.28 0.47
Group -31.46 3.15 -37.63, -25.28 <0.001
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Intercept 49.53 2.41 44.80, 54.26 <0.001
Session number -0.05 0.04 -0.12, 0.03 0.27
Person-centered SD of error -0.48 0.48 -1.41, 0.45 0.31
Group -31.46 3.15 -37.63, -25.28 <0.001
†Reference group: FM
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